S. Pressel

发表

Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, P. Whelton, Mahboob Rahman, 2014 .

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, Jackson T. Wright, J. Williamson, 2002, JAMA.

The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk

B. Davis, P. Whelton, K. Margolis, 2017, Current Cardiology Reports.

Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial

B. Davis, J. Williamson, P. Whelton, 2017, JAMA internal medicine.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, Jackson T. Wright, P. Whelton, 2005, Archives of internal medicine.

Ascertainment of vital status through the National Death Index and the Social Security Administration.

C. Ford, C. M. Hawkins, S. Pressel, 1985, American journal of epidemiology.

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases

H Tunstall-Pedoe, V Tikhonoff, A Hofman, 2007, European Journal of Epidemiology.

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, Jackson T. Wright, P. Whelton, 2008, Archives of internal medicine.

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.

B. Davis, Jackson T. Wright, P. Whelton, 2009, Archives of internal medicine.

Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial

B. Davis, T. S. St. Pierre, R. Ware, 2015, American journal of hematology.

The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications

B. Davis, Jackson T. Wright, P. Whelton, 2018, American journal of hypertension.

Relation of serum vitamins A and E and carotenoids to the risk of cancer.

B. Rosner, M. Stampfer, J. Taylor, 1984, The New England journal of medicine.

Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study

B. Davis, Jackson T. Wright, P. Whelton, 2012, Circulation. Cardiovascular quality and outcomes.

Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, P. Whelton, J. Probstfield, 1998, Controlled clinical trials.

Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT

B. Davis, Mahboob Rahman, J. Basile, 2013, Clinical nephrology.

The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

B. Davis, Mahboob Rahman, J. Coresh, 2004, Archives of internal medicine.

Prevention of Stroke in Older Persons With Isolated Systolic Hypertension-Reply

B. Davis, J. Stamler, J. Probstfield, 1991 .

Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group.

B. Davis, P. Savage, W. Applegate, 1998, Archives of internal medicine.

The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation

B. Davis, D. Arnett, D. Lai, 2019, American Journal of Hypertension.

Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT

B. Davis, J. Graves, Jose-Miguel Yamal, 2014, Journal of hypertension.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

Scott T. Miller, Jamie L. Coleman, B. Davis, 2016, The Lancet.

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial

Scott T. Miller, Jamie L. Coleman, B. Davis, 2015, Lancet (London, England).

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

B. Davis, J. Cutler, P. Savage, 1996, JAMA.

The systolic hypertension in the elderly program

M. Blaufox, B. Davis, R. Mcdonald, 1994 .

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Barry J. Davis, M. Landray, R. Collins, 2022, The Lancet.

Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management

B. Davis, I. Hirsch, D. Lai, 2017 .

Effects of hydroxyurea treatment for patients with hemoglobin SC disease

B. Davis, C. Roberts, C. Thornburg, 2016, American journal of hematology.

Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program

B. Davis, W. Cushman, W. Kostis, 2019, Journal of Human Hypertension.

Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).

B. Davis, L. Kuller, J. Guralnik, 2000, JAMA.

B. Davis, J. Cutler, P. Savage, 1996, JAMA.

Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group.

B. Davis, H. Black, R. Allman, 2000, Archives of internal medicine.

Respiratory Symptoms Secondary to Aortopulmonary Collateral Vessels in Tetralogy of Fallot Absent Pulmonary Valve Syndrome

E. Rapaport, S. Pressel, C. Babcock, 2004 .

Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial

B. Davis, R. Ware, A. Thompson, 2016, British journal of haematology.

TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Scott T. Miller, Jamie L. Coleman, B. Davis, 2015 .

EFFECT OF WEIGHT LOSS ON THE RETURN OF HYPERTENSION AFTER WITHDRAWAL OF PROLONGED ANTIHYPERTENSIVE THERAPY

M. Blaufox, G. Cutter, H. Langford, 1984 .

Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults ALLHAT-LLT randomized clinical trial

B. Davis, J. Williamson, C. Blaum, 2017 .

Return of hypertension after withdrawal of prolonged antihypertensive therapy, effect of weight loss, sodium reduction, and baseline factors.

M. Blaufox, G. Cutter, H. Langford, 1984, Transactions of the Association of American Physicians.

Part 6: Baseline Physical Examination Findings

H. Black, R. Mcdonald, A. Burlando, 1991 .

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, P. Whelton, J. Cutler, 2006, Archives of internal medicine.

Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate

B. Davis, Jackson T. Wright, P. Whelton, 2006, Annals of Internal Medicine.

Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.

W. Applegate, J. Wittes, H. Perry, 1994, Archives of internal medicine.

Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program.

M. Blaufox, N. Borhani, H. Langford, 1987, Archives of internal medicine.

PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCER

W. Willett, B. Rosner, M. Stampfer, 1983, The Lancet.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.

B. Davis, W. Cushman, J. Tobin, 2001, Controlled clinical trials.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Yasuo Ohashi, Paul Welsh, Luigi Tavazzi, 2010, The Lancet.

Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial

B. Davis, J. Williamson, C. Blaum, 2017, JAMA internal medicine.

Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseNovelty and Significance

B. Davis, P. Whelton, Mahboob Rahman, 2014 .

Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.

B. Davis, S. Oparil, W. Cushman, 2014, Journal of the American Society of Hypertension : JASH.

Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, P. Whelton, Mahboob Rahman, 2014, Hypertension.

ALLHAT: still providing correct answers after 7 years

B. Davis, P. Whelton, Mahboob Rahman, 2010, Current opinion in cardiology.

Influence of Long-term, Low-Dose, Diuretic-Based, Antihypertensive Therapy on Glucose, Lipid, Uric Acid, and Potassium Levels in Older Men and Women With Isolated Systolic Hypertension The Systolic Hypertension in the Elderly Program

B. Davis, P. Savage, W. Applegate, 1998 .

Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Michael A. Proschan, Barry R. Davis, Curt D. Furberg, 1996 .

Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly).

B. Davis, W. Applegate, J. Kostis, 1996, Archives of internal medicine.

Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies

J. Gallacher, J. Danesh, O. Franco, 2018, European heart journal.

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

R. Coifman, B. Davis, H. Krumholz, 2017, Hypertension.

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.

B R Davis, B. Davis, P. Whelton, 1996, American journal of hypertension.

Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.

Barry R Davis, B. Davis, P. Whelton, 2010, Archives of internal medicine.

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, Mahboob Rahman, J. Basile, 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL

B. Davis, Mahboob Rahman, J. Basile, 2008 .

Visit‐to‐Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program

B. Davis, W. Kostis, J. Kostis, 2014, Journal of clinical hypertension.

Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

L. Goldman, B. Davis, J. Cutler, 2008, Journal of General Internal Medicine.

Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP).

B. Davis, J. Wittes, E. Lakatos, 1992, Controlled clinical trials.

Long-Term Fatal Outcomes in Subjects With Stroke or Transient Ischemic Attack: Fourteen-Year Follow-Up of the Systolic Hypertension in the Elderly Program

Alan C. Wilson, B. Davis, J. Kostis, 2008, Stroke.

Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

B. Davis, S. Oparil, A. Auchus, 2017, Stroke.

Effect of thiazide-based therapy on serum alkaline phosphatase. Hypertension Detection and Follow-up Group.

H. Langford, K. Schneider, S. Pressel, 1991, Journal of human hypertension.

Systolic Hypertension in the Elderly Program (SHEP). Part 3: Sociodemographic characteristics.

S. Wasserthiel-Smoller, J. Stamler, E. Eddleman, 1991, Hypertension.

Prediction of response to sodium intervention for blood pressure control.

M. Blaufox, G. Cutter, H. Langford, 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.

Alan C. Wilson, B. Davis, J. Kostis, 2005, The American journal of cardiology.

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

D. E. Mathis, B. Davis, P. Whelton, 2005, Archives of internal medicine.

Association between chlorthalidone treatment of systolic hypertension and long-term survival.

Jerry Q. Cheng, B. Davis, J. Kostis, 2011, JAMA.

Mortality and Morbidity During and After the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial

B. Davis, P. Whelton, S. Oparil, 2012, Journal of clinical hypertension.

Dietary therapy slows the return of hypertension after stopping prolonged medication.

M. Blaufox, G. Cutter, H. Langford, 1985, JAMA.

Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).

B. Davis, S. Oparil, L. Haywood, 2016, The American journal of cardiology.

Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project

Barry R Davis, B. Davis, P. Whelton, 2009, Clinical trials.

Effective dietary intervention in hypertensives: sodium restriction and weight reduction.

M. Blaufox, A. Caggiula, H. Langford, 1985, Journal of the American Dietetic Association.

Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes

B. Davis, I. Hirsch, R. Bergenstal, 2015, Diabetes Care.

Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.

B. Davis, P. Whelton, Mahboob Rahman, 2017, The American journal of medicine.

Management of High Blood Pressure in Clinical Practice: Perceptible Qualitative Differences in Approaches Utilized by Clinicians

B. Davis, J. Cutler, E. Roccella, 2008, Journal of clinical hypertension.

Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes.

B. Davis, P. Whelton, Mahboob Rahman, 2018, Journal of diabetes and its complications.

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.

B. Davis, M. Woodward, S. Wild, 2019, European heart journal.

Nosological coding of cause of death.

B. Tung, C. M. Hawkins, S. Pressel, 1983, American journal of epidemiology.

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, C. Furberg, J. Wright, 2001, Controlled clinical trials.

What If Chlorthalidone-Associated Hyperglycemia Develops?—Reply

B. Davis, P. Whelton, J. Cutler, 2007 .

Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk

Dejian Lai, Barry R. Davis, Kelley R. Branch, 2016, Diabetes Care.

Rapid Decreases in Blood Pressure from Antihypertensive Treatment were Associated with Increased Cancer Mortality in the Systolic Hypertension in the Elderly Program

B. Davis, J. Kostis, S. Pressel, 2014, Cancer Epidemiology, Biomarkers & Prevention.